eli lilly oral glp-1 to seek approval of new weight-loss drug this year Lilly's New Oral GLP-1 Orforglipron

GLP-1 medications commonly cause gastrointestinal side effects, particularly during treatment initiation or dose escalation

For weight management, NICE technology appraisals TA875 (semaglutide) and TA664 (liraglutide) recommend these medicines for people meeting certain criteria within specialist weight management services

DSP declares associations to Abbott, Alkaloid, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and Worwag Pharma

Why rotating injection sites is so important Injection technique matters almost as much as the medication itself: Prevents lipohypertrophy: Repeated injections in the same spot can cause scar tissue to form, which cannot fully reverse on its own